|Day's range||0.077 - 0.077|
|52-week range||0.074 - 0.145|
|PE ratio (TTM)||-5.13|
|Dividend & yield||N/A (N/A)|
|1y target est||0.27|
VALENCIA, Calif. & PERTH, Australia & CAMBRIDGE, England--(BUSINESSWIRE)-- Deploying a suspension of cells generated from a ReCell® medical device onto a skin donor site can speed up healing by 30.7% and deliver a superior final outcome, according to the results of a randomized controlled trial involving 106 patients who received skin grafts, Avita Medical (ASX:AVH.AX - News) (OTCQX:AVMXY - News), said today. Avita, a regenerative medicine company focused on the treatment of wounds and skin defects, said the findings reported in the British Journal of Surgery (BJS) further supported its growing data package around its ReCell® autologous cell harvesting device. This is the 3rd randomized controlled trial announced in recent weeks: last month, the Company presented data from two trials conducted at leading burns centers across the US, including successful results from its pivotal trial needed for PMA approval with the Food and Drug Administration.
VALENCIA, Calif. & PERTH, Australia & CAMBRIDGE, England--(BUSINESSWIRE)-- The board of pioneering regenerative medicine company Avita Medical Limited (ASX: AVH ; OTCQX: AVMXY ) has appointed Dr Michael ...
NORTHRIDGE, Calif. & PERTH, Australia & CAMBRIDGE, England--(BUSINESSWIRE)-- The board of pioneering regenerative medicine company Avita Medical Limited (ASX: AVH) (OTCQX: AVMXY), have shown a strong vote of confidence in the company by taking part or all of their Director’s fees in the form of shares. The Board policy of Avita is that individual Directors will invest an amount equivalent to 100% of their annual remuneration over a 3-4 year period. This policy follows from the shareholder approval of the employee share plan in November last year.